BGB324
Showing 1 - 7 of 7
Brain and CNS Tumors Trial in United States (BGB 324 (before surgery), BGB 324 (after surgery))
Active, not recruiting
- Brain and Central Nervous System Tumors
- BGB 324 (before surgery)
- BGB 324 (after surgery)
-
Birmingham, Alabama
- +5 more
Dec 1, 2022
NSCLC Trial in United States (erlotinib, bemcentinib)
Completed
- Non-Small Cell Lung Cancer
-
Los Angeles, California
- +9 more
Aug 16, 2022
Acute Myeloid Leukemia, MDS Trial in Worldwide (Bemcentinib, Cytarabine, Decitabine)
Active, not recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Bemcentinib
- +2 more
-
Iowa City, Iowa
- +11 more
Mar 1, 2022
Mesothelioma, Malignant Trial in Leicester (Rucaparib, Abemaciclib, pembrolizumab & bemcentinib)
Recruiting
- Mesothelioma, Malignant
- Rucaparib
- +4 more
-
Leicester, United KingdomUniversity Hospitals of Leicester NHS Trust
Apr 6, 2022
Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors Trial in United States (Surufatinib and Tislelizumab _ Part 1,
Recruiting
- Metastatic Solid Tumor
- +6 more
- Surufatinib and Tislelizumab _ Part 1
- Surufatinib and Tislelizumab _ Part 2
-
Tucson, Arizona
- +17 more
Apr 1, 2022
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome Trial in France, Germany,
Completed
- Acute Myeloid Leukemia
- +2 more
-
Nantes, Nantes Cedex 1, France
- +7 more
Dec 20, 2021